May 2nd, the FDA will be discussing the use of Merck’s drug Singulair (montelukast) as another allergy medication available over-the-counter. Some of the discussions will be about the proper labeling of adverse events and the exclusive indication for allergy in adults. Currently half of the prescriptions for Singulair are for asthma and over a third of the patients are under the age of 18. How do you feel about Singular status switch as a pharmacist? How often do you counsel patients on products that recently switched to OTC?
For additional information, please see the news analysis in the Associated Press.